• Title of article

    Absence of CNTNAP2 Leads to Epilepsy, Neuronal Migration Abnormalities, and Core Autism-Related Deficits

  • Author/Authors

    Olga Pe?agarikano، نويسنده , , Brett S. Abrahams، نويسنده , , Edward I. Herman، نويسنده , , Kellen D. Winden، نويسنده , , Amos Gdalyahu، نويسنده , , Hongmei Dong، نويسنده , , Lisa I. Sonnenblick، نويسنده , , Robin Gruver، نويسنده , , Joel Almajano، نويسنده , , Anatol Bragin، نويسنده , , Peyman Golshani، نويسنده , , Joshua T. Trachtenberg، نويسنده , , Elior Peles، نويسنده , , Daniel H. Geschwind، نويسنده ,

  • Issue Information
    هفته نامه با شماره پیاپی سال 2011
  • Pages
    12
  • From page
    235
  • To page
    246
  • Abstract
    Although many genes predisposing to autism spectrum disorders (ASD) have been identified, the biological mechanism(s) remain unclear. Mouse models based on human disease-causing mutations provide the potential for understanding gene function and novel treatment development. Here, we characterize a mouse knockout of the Cntnap2 gene, which is strongly associated with ASD and allied neurodevelopmental disorders. Cntnap2−/− mice show deficits in the three core ASD behavioral domains, as well as hyperactivity and epileptic seizures, as have been reported in humans with CNTNAP2 mutations. Neuropathological and physiological analyses of these mice before the onset of seizures reveal neuronal migration abnormalities, reduced number of interneurons, and abnormal neuronal network activity. In addition, treatment with the FDA-approved drug risperidone ameliorates the targeted repetitive behaviors in the mutant mice. These data demonstrate a functional role for CNTNAP2 in brain development and provide a new tool for mechanistic and therapeutic research in ASD.
  • Journal title
    CELL
  • Serial Year
    2011
  • Journal title
    CELL
  • Record number

    1020864